News

PharmExec4h

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.
GlobalData on MSN12h

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...
STAT9h

Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Gilead unit to acquire cell therapy developer Interius for $350 million

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...
TipRanks on MSN7h

Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...
BioPharma Dive1d

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

Gilead Sciences Raises Guidance After Results Top Views

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Coty, Gilead Sciences, Rent the Runway: Trending tickers

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...